Identifying factors contributing to increased susceptibility to COVID-19 risk: a systematic review of Mendelian randomization studies
Open Access
- 20 April 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 51 (4) , 1088-1105
Abstract
Background: To summarize modifiable factors for coronavirus disease 2019 (COVID-19) suggested by Mendelian randomization studies. Methods: In this systematic review, we searched PubMed, EMBASE and MEDLINE, from inception to 15 November 2021, for Mendelian randomization studies in English. We selected studies that assessed associations of genetically predicted exposures with COVID-19-related outcomes (severity, hospitalization and susceptibility). Risk of bias of the included studies was evaluated based on the consideration of the three main assumptions for instrumental variable analyses. Results: We identified 700 studies through systematic search, of which 50 Mendelian randomization studies were included. Included studies have explored a wide range of socio-demographic factors, lifestyle attributes, anthropometrics and biomarkers, predisposition to diseases and druggable targets in COVID-19 risk. Mendelian randomization studies suggested that increases in smoking, obesity and inflammatory factors were associated with higher risk of COVID-19. Predisposition to ischaemic stroke, combined bipolar disorder and schizophrenia, attention-deficit and hyperactivity disorder, chronic kidney disease and idiopathic pulmonary fibrosis was potentially associated with higher COVID-19 risk. Druggable targets, such as higher protein expression of histo-blood group ABO system transferase (ABO), interleukin (IL)-6 and lower protein expression of 2′-5′ oligoadenylate synthetase 1 (OAS1) were associated with higher risk of COVID-19. There was no strong genetic evidence supporting the role of vitamin D, glycaemic traits and predisposition to cardiometabolic diseases in COVID-19 risk. Conclusion: This review summarizes modifiable factors for intervention (e.g. smoking, obesity and inflammatory factors) and proteomic signatures (e.g. OAS1 and IL-6) that could help identify drugs for treating COVID-19.Keywords
This publication has 120 references indexed in Scilit:
- UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old AgePLOS Medicine, 2015
- Bayesian Test for Colocalisation between Pairs of Genetic Association Studies Using Summary StatisticsPLOS Genetics, 2014
- Mendelian Randomization and Estimation of Treatment Efficacy for Chronic DiseasesAmerican Journal of Epidemiology, 2013
- Avoiding bias from weak instruments in Mendelian randomization studiesInternational Journal of Epidemiology, 2011
- Common polygenic variation contributes to risk of schizophrenia and bipolar disorderNature, 2009
- Basophils enhance immunological memory responsesNature Immunology, 2008
- Clustered Environments and Randomized Genes: A Fundamental Distinction between Conventional and Genetic EpidemiologyPLOS Medicine, 2007
- Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese populationBiochemical and Biophysical Research Communications, 2005
- Effects of inflammatory cytokines on the release and cleavage of the endothelial cell–derived ultralarge von Willebrand factor multimers under flowBlood, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003